PMI AI White Paper Warns of “Cognitive Atrophy” and Attention Erosion, Calls for Focus on Human Cognition’s Evolution

Jan.21
PMI AI White Paper Warns of “Cognitive Atrophy” and Attention Erosion, Calls for Focus on Human Cognition’s Evolution
Philip Morris International (PMI) has released a white paper calling for cross-sector dialogue on how AI may affect human cognitive abilities. The paper flags risks including “cognitive atrophy” and attention erosion, and warns of a widening cognitive divide and rising pressures on information verification and trust.

Key Takeaways

 

  • PMI has released a white paper calling for cross-sector dialogue on how human cognition will evolve—and how it should be governed—in the age of AI.
  • It argues that as AI moves deeper into knowledge work, “human advantage” capabilities such as critical thinking, creativity and adaptability will become more important.
  • The paper identifies two main risks: “cognitive atrophy,” as generative AI substitutes for thinking processes, and “attention erosion,” driven by information feeds and synthetic content.
  • It warns that a “cognitive divide” could widen and that deepfakes and other synthetic media will intensify pressures on trust and verification.

 


2Firsts, January 21, 2026

 

According to Business Wire, Philip Morris International (PMI) released a white paper on Jan. 20 in Stamford, Connecticut, titled Human Cognition: The Next Frontier? (Chinese: Human Cognition: The Next Frontier?), calling for cross-sector discussion on “how human cognitive abilities will evolve” as artificial intelligence continues to reshape the way work, society and economies function.

 

The white paper argues that as AI increasingly automates routine tasks and expands into knowledge-work processes, capabilities such as critical thinking, creativity and adaptability will become more important. It says organizations need to reassess how to develop and protect human cognitive abilities.

 

The document also outlines what it describes as “accelerating cognitive risks.” It defines “cognitive atrophy” as the substitution effect of generative AI in ideation, drafting and analysis, which could reduce deep thinking and independent judgment built through sustained mental effort. It describes “attention erosion” as the impact of always-on environments—notifications, information feeds, dashboards and synthetic content—that can fragment attention and weaken sustained focus and complex reasoning.

 

In addition, the paper raises the prospect of an “emerging cognitive divide,” arguing that disparities in access to time, focus and advanced learning resources may widen and become entrenched as a new form of inequality in the AI era. It also warns that the growth of synthetic media and deepfakes will create “trust and verification challenges,” requiring new habits of information verification and stronger digital skepticism.

 

Cover image source: Business Wire

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Mexico to impose an absolute ban on the commercialization, import and sale of vapes from Jan. 16, 2026
Mexico to impose an absolute ban on the commercialization, import and sale of vapes from Jan. 16, 2026
Mexico will enforce an absolute ban on the commercialization, import and sale of vapes and e-cigarettes from January 16, 2026, under a reform published in the Official Journal of the Federation (DOF) amending the General Health Law.
Jan.16 by 2FIRSTS.ai
Andy Tan Named 2026 SRNT Fellow for Contributions to Nicotine Research
Andy Tan Named 2026 SRNT Fellow for Contributions to Nicotine Research
Andy Tan, Ph.D., has been named a 2026 Fellow of the Society for Research on Nicotine and Tobacco (SRNT), an international professional association dedicated to advancing nicotine and tobacco research. Fellows are selected for outstanding research contributions as well as leadership, mentoring, and policy engagement within the field.
Feb.23
Uzbekistan to impose full ban on nicotine delivery devices from March 1,2026
Uzbekistan to impose full ban on nicotine delivery devices from March 1,2026
Uzbekistan will enforce a total ban on the circulation of electronic nicotine delivery systems from March 1, covering legal sales, storage and imports. Consumers are offered a legal option to avoid criminal liability by voluntarily handing prohibited devices to law enforcement. The report says imports had already effectively stalled in early 2025, leaving sellers to clear remaining stock.
Feb.27 by 2FIRSTS.ai
Cambodia’s tobacco industry association ATIC appoints JTI Cambodia GM as president
Cambodia’s tobacco industry association ATIC appoints JTI Cambodia GM as president
The Association of Tobacco Industry of Cambodia (ATIC) said JTI Cambodia General Manager Benjamin Cerletti has assumed the role of President following the completion of a two-year term served by his predecessor, Imperial Brands Plc.
Mar.05 by 2FIRSTS.ai
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International (PMI) said its U.S.-related investments have topped $20 billion since 2022, when it entered the U.S. market through its roughly $19 billion acquisition of Swedish Match. The company also said it plans to launch its heated tobacco product IQOS ILUMA in the United States pending authorization from the U.S. Food and Drug Administration (FDA).
Jan.16 by 2FIRSTS.ai
2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
As the FDA advances efforts to streamline its PMTA review process, including support for small businesses, expectations are rising that additional product authorizations may follow. Age-verification technology is emerging as a key consideration in future approvals.In this interview, California-based Glas discusses its G2 platform, integrating smartphone-based identity verification, proximity controls and anti-counterfeit systems, and outlines its positioning under the FDA’s PMTA framework.
Mar.02